MA32479B1 - Compoés nouveaux actifs comme antagonistes des recepteurs muscariniques - Google Patents

Compoés nouveaux actifs comme antagonistes des recepteurs muscariniques

Info

Publication number
MA32479B1
MA32479B1 MA33523A MA33523A MA32479B1 MA 32479 B1 MA32479 B1 MA 32479B1 MA 33523 A MA33523 A MA 33523A MA 33523 A MA33523 A MA 33523A MA 32479 B1 MA32479 B1 MA 32479B1
Authority
MA
Morocco
Prior art keywords
receptor antagonists
muscarinic receptor
new active
compounds new
compounds
Prior art date
Application number
MA33523A
Other languages
Arabic (ar)
English (en)
Inventor
Paul Alan Glossop
Charlotte Alice Louise Lane
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of MA32479B1 publication Critical patent/MA32479B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention porte sur des composés de formule (i), sur des procédés et intermédiaires pour les préparer, sur leur utilisation comme antagonistes muscariniques et sur des compositions pharmaceutiques les contenant.
MA33523A 2008-07-15 2011-01-14 Compoés nouveaux actifs comme antagonistes des recepteurs muscariniques MA32479B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8072608P 2008-07-15 2008-07-15
PCT/IB2009/052859 WO2010007552A1 (fr) 2008-07-15 2009-07-01 Nouveaux composés actifs comme antagonistes des récepteurs muscariniques

Publications (1)

Publication Number Publication Date
MA32479B1 true MA32479B1 (fr) 2011-07-03

Family

ID=41139473

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33523A MA32479B1 (fr) 2008-07-15 2011-01-14 Compoés nouveaux actifs comme antagonistes des recepteurs muscariniques

Country Status (28)

Country Link
US (1) US20100016366A1 (fr)
EP (1) EP2328868A1 (fr)
JP (1) JP2011528346A (fr)
KR (1) KR20110017452A (fr)
CN (1) CN102099334A (fr)
AP (1) AP2010005512A0 (fr)
AR (1) AR072802A1 (fr)
AU (1) AU2009272303B2 (fr)
BR (1) BRPI0915753A2 (fr)
CA (1) CA2727769A1 (fr)
CL (1) CL2011000093A1 (fr)
CO (1) CO6321246A2 (fr)
CR (1) CR11828A (fr)
DO (1) DOP2011000017A (fr)
EA (1) EA201001842A1 (fr)
EC (1) ECSP11010753A (fr)
HN (1) HN2009001330A (fr)
IL (1) IL210293A0 (fr)
MA (1) MA32479B1 (fr)
MX (1) MX2011000588A (fr)
NI (1) NI201100015A (fr)
NZ (1) NZ589934A (fr)
PE (1) PE20110312A1 (fr)
SV (1) SV2011003808A (fr)
TW (1) TW201006799A (fr)
UY (1) UY31980A (fr)
WO (1) WO2010007552A1 (fr)
ZA (1) ZA201100841B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011083387A1 (fr) * 2010-01-07 2011-07-14 Pfizer Limited Sel de chlorhydrate du biphényl-2-yl-carbamate de 1-{9-[(3-fluoro-4-hydroxy-benzoyl)-méthyl-amino]-nonyl}-pipéridin-4-yle
MX2012011395A (es) * 2010-04-01 2013-02-26 Theravida Inc Metodos de mejoramiento de la calidad del sueño.
CN107074816B (zh) * 2015-03-27 2020-07-17 四川海思科制药有限公司 一种杂环衍生物及其制备方法和在医药上的用途
WO2016180348A1 (fr) * 2015-05-14 2016-11-17 四川海思科制药有限公司 Dérivé spiro-hétérocyclique contenant de l'azote présentant des activités d'excitation de récepteur bêta2 et des activités antagonistes au récepteur m et son application dans un médicament
CN106336406B (zh) * 2015-07-10 2020-01-03 四川海思科制药有限公司 具有β2受体激动及M受体拮抗活性的八氢并环戊二烯衍生物及其在医药上的用途
WO2019071147A1 (fr) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. Inhibiteurs de la kinase p38 réduisant l'expression du gène dux4 et des gènes aval pour le traitement de la fshd
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20040950A1 (es) * 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
JP2009534463A (ja) * 2006-04-24 2009-09-24 アストラゼネカ・アクチエボラーグ 例えば慢性気管支閉塞、喘息および過活動膀胱の処置に有用な、ムスカリンｍ３受容体アンタゴニスト活性を有する環状アミノアルコールの新規アルキルエステル

Also Published As

Publication number Publication date
AU2009272303A1 (en) 2010-01-21
AR072802A1 (es) 2010-09-22
BRPI0915753A2 (pt) 2015-11-03
CN102099334A (zh) 2011-06-15
DOP2011000017A (es) 2011-02-15
KR20110017452A (ko) 2011-02-21
NI201100015A (es) 2011-08-05
HN2009001330A (es) 2012-04-02
ECSP11010753A (es) 2011-02-28
CL2011000093A1 (es) 2011-05-06
US20100016366A1 (en) 2010-01-21
MX2011000588A (es) 2011-03-01
EA201001842A1 (ru) 2011-08-30
JP2011528346A (ja) 2011-11-17
CA2727769A1 (fr) 2010-01-21
WO2010007552A1 (fr) 2010-01-21
ZA201100841B (en) 2011-10-26
SV2011003808A (es) 2011-03-23
CR11828A (es) 2011-01-10
AU2009272303B2 (en) 2011-12-22
IL210293A0 (en) 2011-03-31
PE20110312A1 (es) 2011-06-25
CO6321246A2 (es) 2011-09-20
NZ589934A (en) 2012-06-29
EP2328868A1 (fr) 2011-06-08
AP2010005512A0 (en) 2010-12-31
UY31980A (es) 2010-02-26
TW201006799A (en) 2010-02-16

Similar Documents

Publication Publication Date Title
EA201001205A1 (ru) Соединения, содержащие циклобутоксигруппу
GEP20156266B (en) Spiroheterocyclic n-oxypiperidines as pesticides
EA201170772A1 (ru) Органические соединения
EA200970612A1 (ru) Производные индола в качестве агонистов рецептора s1p1
EA201290940A1 (ru) Новые соединения как селективные антагонисты рецептора nk3, фармацевтическая композиция и методы их использования при нарушениях, опосредованных nk3 рецепторами
MX2011008864A (es) Tetrahidroazolopirazinas sulfoniladas y su uso como productos medicinales.
EA200970967A1 (ru) Оксадиазол замещенные производные индазола для применения в качестве агонистов сфингозин 1-фосфата (sip)
EA201190235A1 (ru) Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750
EA201001680A1 (ru) Соединения бензолсульфонамидтиазола и оксазола
EA201270216A1 (ru) Фармацевтический состав
MA32479B1 (fr) Compoés nouveaux actifs comme antagonistes des recepteurs muscariniques
MX2008002805A (es) Derivados de carboxamida como antagonistas del receptor muscarinico.
EA201071329A1 (ru) Диамидные производные адамантана и их применение
EA201100161A1 (ru) Производные хинуклидина карбоната и их медицинские композиции
JO2770B1 (en) Organic compounds
WO2009104021A3 (fr) Nouveaux polymorphes et procédés de préparation
EA200971140A1 (ru) Триарильные соединения и композиции, их содержащие
MX349156B (es) Formas cristalinas y procesos para la preparacion de fenil-pirazoles utiles como moduladores del receptor de serotonina 5-ht2a.
UA112973C2 (uk) Складноефірні проліки [3-(1-(1h-імідазол-4-іл)етил)-2-метилфеніл]метанолу
TW200609221A (en) 4-substituted quinoline derivatives, method and intermediates for their preparation and pharmaceutical compositions containing them
EA200900090A1 (ru) Бензиламины, способ их получения и их применение в качестве противовоспалительных средств
EA201001855A1 (ru) Соединения, содержащие циклобутоксигруппу
MX2009008028A (es) Agentes antiparasitarios.
MA32945B1 (fr) Tétrahydropyrane spiro pyrrolidinone et pipéridinone substituées, leur préparation et leur utilisation thérapeutique
EA201001566A1 (ru) Новый класс спиропиперидинов для лечения нейродегенеративных заболеваний